Physician profile
Alon E Baker
NPI 1033163928
$2,622.01
in general payments reported to CMS, 2019-2025
25 companies · $357 in 2025
The $357 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $190 · 2021: $573 · 2022: $470 · 2023: $380 · 2024: $422 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $447.89 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $384.17 | 2021-2023 | Qelbree |
| Corium, LLC | $239.48 | 2022-2024 | Azstarys |
| Pfizer INC. | $226.33 | 2019-2025 | |
| Neos Therapeutics, Lp | $137.10 | 2019-2022 | |
| Tris Pharma INC | $135.35 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $131.78 | 2020-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Alk-Abello, INC | $120.93 | 2023-2025 | Neffy, Odactra, Ragwitek |
| Sanofi-Aventis U.S. LLC | $97.00 | 2024-2025 | |
| Cranial Technologies, INC | $92.16 | 2022-2025 | Doc Band |
| Adlon Therapeutics L.P. | $82.54 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.19 | 2020-2021 | |
| Glaxosmithkline, LLC. | $73.67 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $55.47 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $55.38 | 2019-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $50.31 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $44.50 | 2022-2023 | Flumist Quadrivalent |
| Seqirus USA INC | $44.06 | 2022-2025 | Fluad, Flucelvax, Flucelvax Quadrivalent |
| Phadia US INC. | $30.07 | 2019-2023 | Immunocap |
| Biogen, INC. | $23.00 | 2020 | |
| Genentech USA, INC. | $14.54 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.44 | 2019 | |
| Shire North American Group INC | $13.81 | 2019 | |
| Qol Medical, LLC | $13.78 | 2019 | |
| Sobi, INC | $13.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alon Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.